Salute e Benessere
ANGPTL3 Inhibitor Market Set for Robust Growth During the Forecast Period (2025-2034) Across 7MM Owing to the Rising Demand for Novel Lipid-Lowering Therapies | DelveInsight
Discover which therapies are expected to grab the ANGPTL3 inhibitor market share @
The ANGPTL3 inhibitors market is emerging as a promising niche within the broader cardiovascular and lipid-lowering therapeutics landscape. ANGPTL3 is a critical regulator of , and its inhibition results in substantial reductions in triglycerides, LDL-C, and other atherogenic lipids. This mechanism is particularly attractive for , mixed dyslipidemia, or those who are unresponsive to traditional therapies such as . As a result, the market for ANGPTL3-targeted therapies is being driven by the and the .
Currently, , a monoclonal antibody developed by , is the first and only FDA-approved ANGPTL3 inhibitor, indicated for homozygous familial hypercholesterolemia (HoFH). Its success has validated ANGPTL3 as a therapeutic target and opened the door for further innovation. However, Evinacumab is a , which presents challenges for broader adoption. Consequently, the market is seeing , such as antisense oligonucleotides (ASOs) and siRNA therapies.
The market dynamics are also shaped by , especially for rare diseases like HoFH. These incentives have attracted biotech and pharmaceutical companies to invest in the space despite the relatively small patient populations. In parallel, is expanding toward more common indications, including severe hypertriglyceridemia, mixed dyslipidemia, and nonalcoholic fatty liver disease (NAFLD), which could significantly increase the addressable market in the next 5–10 years.
However, there are notable barriers to growth. remain key challenges, especially for biologics like Evinacumab. Furthermore, are still limited, which could affect physician adoption and payer support. such as statins, ezetimibe, PCSK9 inhibitors, and even emerging bempedoic acid also pressures market expansion. The ability of ANGPTL3 inhibitors to carve out their place will depend on demonstrating superior or complementary efficacy, improved patient outcomes, and cost-effectiveness.
In summary, the ANGPTL3 inhibitors market is at an inflection point—buoyed by strong scientific rationale and early regulatory success but tempered by commercial and clinical challenges. The next phase of growth will hinge on pipeline innovation, broader indication approvals, and real-world data that reinforce the value proposition of this novel class of lipid-lowering agents. As the cardiovascular therapeutic landscape evolves toward more targeted and personalized approaches, ANGPTL3 inhibitors are poised to play a critical role.
Currently, only one ANGPTL3 inhibitor has received approval — . EVKEEZA is a fully human monoclonal antibody that targets and inhibits the activity of ANGPTL3, a protein involved in lipid metabolism. The angiopoietin gene family, including ANGPTL3, was first identified by Regeneron scientists over 20 years ago. Research published in the New England Journal of Medicine in 2017 by the Regeneron Genetics Center revealed that individuals with a loss-of-function mutation in the ANGPTL3 gene had significantly lower levels of key blood lipids, such as LDL cholesterol, and a reduced risk of developing coronary artery disease.
Developed using Regeneron's VelocImmune technology—which employs genetically engineered mice with humanized immune systems—EVKEEZA produces fully human antibodies optimized for therapeutic use. In March 2023 , the FDA expanded the approval of EVKEEZA for use as an add-on to other cholesterol-lowering treatments in children aged 5 to 11 years who have homozygous familial hypercholesterolemia.
Learn more about the FDA-approved ANGPTL3 inhibitor @
Major ANGPTL3 inhibitors companies, such as (ALN-ANG3), (Zodasiran), (VERVE-201), (Solbinsiran), and others, are involved in developing therapies for ANGPTL3 inhibitors for various cardiology indications, such as HoFH, severe hypertriglyceridemia, ASCVD, and others, respectively. Overall, this is an exciting new class of technology with great potential for development. The maturation of current studies over the next few years will lead to a better understanding of ANGPTL3 inhibitors and define their role in cardiology.
is a first-in-class investigational RNA interference (RNAi) therapeutic aimed at reducing the production of ANGPTL3. Currently, two clinical trials are evaluating zodasiran as an ANGPTL3 inhibitor. The first, titled "Study of ARO-ANG3 in Adults with Mixed Dyslipidemia (ARCHES-2)", is a randomized, double-blind, placebo-controlled Phase IIb trial assessing the safety and effectiveness of ARO-ANG3 in adults with mixed dyslipidemia. It is listed on ClinicalTrials.gov with the identifier NCT04832971.
The second trial, "Study of ARO-ANG3 in Participants with HoFH (GATEWAY)", is a Phase II study evaluating the safety and efficacy of ARO-ANG3 in individuals with homozygous familial hypercholesterolemia.
is an experimental therapy designed to target the ANGPTL3 gene, which plays a central role in regulating cholesterol and triglyceride levels in the liver. By disrupting the production of the ANGPTL3 protein, this approach may lower LDL cholesterol and remnant cholesterol through a mechanism that differs from that of PCSK9 inhibitors. The treatment leverages a proprietary GalNAc-LNP delivery system to transport a base editor specifically targeting the ANGPTL3 gene into liver cells.
In individuals with homozygous familial hypercholesterolemia (HoFH)—a rare genetic condition marked by extremely elevated LDL-C levels—standard LNP delivery to the liver is ineffective due to the lack of LDL receptors (LDLR), which are essential for LNP uptake. To overcome this limitation, Verve Therapeutics has engineered GalNAc-modified LNPs that bind to asialoglycoprotein receptors (ASGPR) on liver cells, enabling efficient delivery in HoFH patients.
VERVE-201 is being advanced to treat two major ASCVD indications with high unmet needs: HoFH and refractory hypercholesterolemia. The latter includes ASCVD patients who fail to reach recommended LDL-C targets despite being on the highest tolerated doses of standard therapies. Currently, the Pulse-1 Phase Ib trial is underway to assess the safety and tolerability of VERVE-201 in adults with refractory hypercholesterolemia.
The anticipated launch of these emerging therapies are poised to transform the ANGPTL3 inhibitor market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the ANGPTL3 inhibitor market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about ANGPTL3 inhibitor clinical trials, visit @
Angiopoietin-like protein 3 (ANGPTL3) inhibitors are a promising class of lipid-lowering therapies that target a key regulator of lipid metabolism. ANGPTL3 is primarily produced in the liver and functions to inhibit lipoprotein lipase (LPL) and endothelial lipase, enzymes that play crucial roles in the breakdown of triglycerides and cholesterol-rich lipoproteins. By inhibiting ANGPTL3, these drugs effectively lower levels of triglycerides, LDL cholesterol, and other atherogenic lipoproteins, making them especially beneficial for patients with familial hypercholesterolemia or mixed dyslipidemia who may not fully respond to conventional lipid-lowering agents like statins or PCSK9 inhibitors. Multiple therapeutic approaches have been developed to inhibit ANGPTL3, including monoclonal antibodies, antisense oligonucleotides, and RNA interference (RNAi) therapies
The estimated cases of severe hypertriglyceridemia in the US were in 2024. The ANGPTL3 inhibitor market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Discover more about ANGPTL3 inhibitor in development @
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PCSK9 inhibitor companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PCSK9 inhibitors companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key familial hypercholesterolemia companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key homozygous familial hypercholesterolemia companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/angptl3-inhibitor-market-set-for-robust-growth-during-the-forecast-period-20252034-across-7mm-owing-to-the-rising-demand-for-novel-lipid-lowering-therapies--delveinsight-302429994.html